Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
cAMPfield harvests $180M series A to advance oral IBD asset
The money will help advance cAMPfield’s lead candidate, an oral PDE4 inhibitor licensed from China’s Newsoara, for the treatment of IBD.
Angus Liu
Jun 18, 2026 10:34am
Affibody gets izokibep ‘back on track’ after Acelyrin rejection
Jun 5, 2026 10:42am
Boehringer makes €407M bet on Immunitas’ inflammatory asset
May 12, 2026 9:57am
Avalo’s phase 2 win fuels AbbVie chase despite placebo headwind
May 6, 2026 6:00am
Windward breezes toward phase 3 with $165M for TSLP ambitions
May 4, 2026 10:31am
Lipella goes bankrupt, ending mouth inflammation drug ambitions
Mar 31, 2026 7:20am
